leadf
logo-loader
viewCreso Pharma Ltd

Creso Pharma’s subsidiary Mernova Medicinal expanding operations to target growing Canadian hash market

Feedback from end-users and resellers is that initial orders will occur immediately upon Mernova’s launch into hash.

Creso Pharma Ltd - Creso Pharma’s subsidiary Mernova Medicinal Inc to expand operations to target the growing Canadian hash market
Canada's legal hash market is emerging and expected to grow rapidly in the near-term, providing an opportunity to emerge as a market leader

Creso Pharma Ltd’s (ASX:CPH) (OTCMKTS:COPHF) (FRA:1X8) wholly-owned Canadian subsidiary, Mernova Medicinal Inc has made a strategic decision to expand its current operations and target the Canadian hash market. 

The decision follows a comprehensive review of the significant market opportunities available across Canada and very positive customer feedback regarding Mernova’s current product range. 

Feedback from end-users and resellers is that initial orders will occur immediately upon Mernova’s launch into hash. 

The legal hash market in Canada is currently under-supplied and lacks high-quality products despite significant demand. 

Launch of hash products early 2021

Mernova managing director Jack Yu said: “The introduction of 2.0 products to our existing line of premium offerings will further diversify our current range, increase the options available to consumers and provide additional sources of revenue to Mernova.

“In order to best preserve the quality and natural characteristics of the cannabis utilised, we will be focusing on 2.0 products that require little or no processing.

“We look forward to launching our premium hash and pre-roll joints in early 2021.”

Can be legally produced and sold

Hash, a chemical-free, solventless extract produced by physically separating and collecting trichomes from cannabis flowers and applying heat and pressure, can now be legally produced and sold in Canada.

It has the ability to improve and appreciate, with age, and if properly stored, can be kept for up to 12 years or longer.

Being a concentrate, it has higher cannabinoid content than the starting material.

Opportunity to emerge as market leader

Mernova will work to capitalise on this growing demand for hash and further diversify its product lines and identify opportunities to progress sales in various provinces/territories across Canada, including its current markets of Nova Scotia and the Yukon, as well as the imminent and future markets of Ontario and New Brunswick.

The company has received considerable interest in its soon-to-be-launched hash products to date.

The Canadian legal hash market is emerging and anticipated to grow rapidly in the near-term, providing Mernova with an opportunity to emerge as a market leader.

Mernova will progress production of premium hash from its state of the art facility in Windsor, Nova Scotia, with the launch of the new products expected to occur in the first quarter of 2021.

Growing interest in hash globally

Hash has recently grown in popularity in the legal market across Canada, as part of the new wave of cannabis-derived products.

In the US, hash use is on the rise due to an overall increase in global interest in cannabis, increased availability due to legalisation in many states, and demand among older consumers familiar with the cannabis concentrate.

In Europe, the black market for hash is one of the world's largest and most profitable, worth an estimated €2.3 billion in 2017.

Quick facts: Creso Pharma Ltd

Price: 0.2 AUD

ASX:CPH
Market: ASX
Market Cap: $190.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Creso Pharma Ltd named herein, including the promotion by the Company of Creso Pharma Ltd in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Creso Pharma subsidiary Mernova granted sales license from Health Canada

Creso Pharma (ASX:CPH) subsidiary Mernova managing director Jack Yu and vice president Isaac Allen joined Steve Darling from Proactive to discuss the granting of their sales license from Health Canada and what it allows them to do. Isaac Allen tells Proactive they are gearing up sales...

on 12/6/20

3 min read